# US 12,180,550 B2 · Gene signatures for the prediction of prostate cancer recurrence

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,180,550 B2
- Document ID: US12180550B2
- Status: Granted
- Kind: B2
- Application number: 17/292,748
- Filed: 2019-11-08
- Published: 2021-12-23
- Granted: 2024-12-31
- Earliest claimed: 2018-11-13
- Assignees: Bracco Imaging S.P.A.
- Applicants: Bracco Imaging S.P.A.
- Inventors: Andrea Ferraris; Erika Reitano; Alessandro Maiocchi
- Web page: https://patentgrep.com/patent/US12180550B2

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Disclosed are gene signatures and methods for predicting the recurrence of prostate cancer in prostatectomized subjects. Other objectives of the invention are assay devices and kits for determining the expression levels of specific gene sets correlated to prostate cancer recurrence.

## Claims

### Claim 1

An assay device comprising an array consisting of multiple polynucleotide probes complementary and/or hybridizable to the mRNAs of ACADVL, CARHSP1, CNTNAP1, DNASE1L2, RNF103, SEZ6L, SLC22A6, UGGT2, WDR52, and optionally one or more selected from ATP5D, C14orf109, CCDC144A, CDH15, CELSR3, DDX5, EHD4, EPHB3, LOC100508936, PABPC1, PIP4K2C, and PLCG1 genes, wherein the multiple polynucleotide probes are immobilized on a solid support.

### Claim 2 (depends on 1)

The assay device according to claim 1, wherein said multiple polynucleotide probes are complementary and/or hybridizable to the mRNAs of ACADVL, CARHSP1, CNTNAP1, DNASE1L2, RNF103, SEZ6L, SLC22A6, UGGT2, and WDR52 genes.

### Claim 3 (depends on 1)

The assay device according to claim 1, wherein said multiple polynucleotide probes are consist of sequences complementary and/or hybridizable to the mRNAs of ACADVL, CARHSP1, CCDC144A, CNTNAP1, DDX5, DNASE1L2, EHD4, PIP4K2C, RNF103, SEZ6L, SLC22A6, UGGT2, and WDR52 genes.

### Claim 4 (depends on 1)

The assay device according to claim 1, wherein said multiple polynucleotide probes are complementary and/or hybridizable to the mRNAs of ACADVL, C14orf109, CARHSP1, CCDC144A, CDH15, CELSR3, CNTNAP1, DDX5, DNASEIL2, EHD4, PABPC1, PIP4K2C, RNF103, SEZ6L, SLC22A6, UGGT2, and WDR52 genes.

### Claim 5 (depends on 1)

The assay device according to claim 1, wherein said multiple polynucleotide probes are complementary and/or hybridizable to the mRNAs of ACADVL, ATP5D, C14orf109, CARHSP1, CCDC144A, CDH15, CELSR3, CNTNAP1, DDX5, DNASE1L2, EHD4, EPHB3, LOC100508936, PABPC1, PIP4K2C, PLCG1, RNF103, SEZ6L, SLC22A6, UGGT2, and WDR52 genes.

### Claim 6 (depends on 1)

The assay device according to claim 1, wherein the array is a microarray and the multiple polynucleotide probes are immobilized on a solid glass substrate or membrane in separate locations or spots.

### Claim 7 (depends on 1)

A kit containing the assay device according to claim 1 and at least one reagent.

### Claim 8 (depends on 7)

The kit according to claim 7, wherein the reagent comprises a labeled primer, a nucleotide, or a combination thereof.

### Claim 9 (depends on 8)

The kit according to claim 8, wherein the reagent comprises biotin labeled dNTPs.

### Claim 10 (depends on 7)

The kit according to claim 7, further comprising at least one enzyme.

### Claim 11 (depends on 10)

The kit according to claim 10, wherein the at least one enzyme comprises a reverse transcriptase.